Nasal Nanomedicine Shows Major Promise Against Deadly Brain Cancer

Researchers at Washington University School of Medicine and Northwestern University have unveiled a groundbreaking way to deliver cancer-fighting medicine directly to brain tumors — through simple nasal drops. The approach, tested successfully in mice, bypasses the brain’s toughest defenses and activates a powerful immune response against glioblastoma, the most aggressive form of brain cancer.

---

Why Glioblastoma Is So Hard to Treat

Glioblastoma affects approximately three people per 100,000 annually in the United States and remains one of oncology’s most challenging diseases. Originating from astrocytes — star-shaped cells that support brain function — the cancer spreads rapidly and is notoriously difficult to treat.

Standard treatments such as surgery, radiation, and chemotherapy offer limited benefit. The biggest obstacle is the blood–brain barrier, a protective membrane that prevents most drugs from entering brain tissue.
This same barrier makes many potentially life-saving therapies ineffective.

Compounding the challenge, glioblastoma creates a severely immunosuppressed or “cold” tumor environment — a setting in which the body’s immune cells struggle to recognize and attack cancer. Fewer than 7% of patients survive beyond five years after diagnosis.

---

How the Nasal Drops Work

The experimental nasal therapy centers on spherical nucleic acids (SNAs) — tiny nanostructures made of a gold core wrapped in DNA strands. These SNAs are engineered to activate the cGAS-STING immune pathway, a natural defense mechanism that alerts the body to threats.

Instead of being injected into the brain, the SNAs are delivered as nasal drops, taking advantage of the trigeminal nerve that provides a direct conduit from the nasal cavity to the brain. This unique route allows the medicine to bypass the blood–brain barrier entirely, reaching tumors without spreading widely through the bloodstream.

Researchers note that because the medicine concentrates around the tumor and lymphatic tissues, the risk of systemic side effects is significantly reduced.

---

Triggering the Immune System to Attack Tumors

Once inside the brain, SNAs attach to the cGAS protein on immune cells near the tumor. This activates STING, which prompts the production of interferons, the immune system’s early-warning molecules.

This ripple effect recruits a range of cancer-killing cells, including:

• Microglia

• Macrophages

• Cytotoxic T cells

• Natural killer cells

The result is a local, highly targeted immune assault on glioblastoma cells. Importantly, the immune activation remains localized, avoiding widespread inflammation.

---

Breakthrough Results in Pre-Clinical Studies

In mice implanted with glioblastoma, a single dose of the nasal drops generated a strong anti-tumor immune response and significantly slowed tumor growth.

When paired with T-cell–stimulating immunotherapies, the combined treatment:

• Completely eradicated tumors, and

• Produced a lasting immune memory that prevented recurrence.

To ensure the nasal drops were not distributing throughout the body, scientists used near-infrared imaging to track nanoparticle movement. The drug remained concentrated in the brain and nearby tissues — a key safety advantage over existing STING-based therapies.

Experts say the therapy is especially promising for “cold” tumors like glioblastoma, which typically resist immunotherapy. The nasal nanomedicine effectively converts them into “hot” tumors that the immune system can recognize and destroy.

---

Human Trials Still Ahead

Although results in animals are striking, the therapy has not yet entered human trials.
Lead investigator Dr. Alexander Stegh emphasized that researchers must refine the formulation, assess long-term safety, and determine whether the nasal-to-brain pathway functions similarly in humans.

Future studies will explore:

• Optimal dosage and frequency

• Patient selection

• Whether the therapy works best alongside current treatments such as surgery or radiation

• Potential immune-related side effects with repeated dosing

---

Remaining Challenges

Several barriers must still be overcome before nasal nanomedicine can be used in clinics:

• Human brain anatomy may alter drug pathways

• Individual tumors differ widely in immune responsiveness

• The human blood–brain barrier may behave differently

• Long-term immune effects must be monitored closely

Despite these challenges, experts see enormous potential. The technique merges advanced nanotechnology with precision immunotherapy and offers a simpler, safer alternative to invasive brain injections.

---

A Potential Turning Point for Brain Cancer Treatment

The development of nasal-administered spherical nucleic acids represents a major leap in cancer immunotherapy. By reaching the brain without surgery and activating localized anti-tumor immunity, the approach addresses many of the core failures of past treatments.

While still in early stages, the research opens a promising path toward noninvasive, effective therapies for devastating brain cancers — and could one day change how clinicians deliver medicine to the brain.